IASO Biotherapeutics
IASO reported first-in-human Phase 1 data for BCMA-directed IASO206 in relapsed/refractory myeloma at IMS 2026. It also partners with Umoja on CD22 programs with territorial rights. IASO206 and Umoja’s CD22 UB-VV400 are different programs.
Corporate information
- Company entity
- IASO Biotherapeutics
- Headquarters / principal office
- No verified public location identified
- Founded
- 2017 ↗
- Ownership / capital status
- PrivateSeries C2 (September 2025 historical disclosure) ↗
- Official corporate reference
- https://cn.iasobio.com/info.php?id=388 ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2025-09 · Series C2 · CNY 215 million ↗
Company timeline specifies September 2025 only; no day is invented.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
IASO reported first-in-human Phase 1 data for BCMA-directed IASO206 in relapsed/refractory myeloma at IMS 2026. It also partners with Umoja on CD22 programs with territorial rights. IASO206 and Umoja’s CD22 UB-VV400 are different programs.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- 2026 IMS｜驯鹿生物正式发布靶向BCMA In Vivo CAR-T细胞治疗产品IASO206首次人体研究数据 公司新闻 - 驯鹿生物
- IASO Biotherapeutics — supporting primary disclosure
- Corporate ownership / financing disclosure